Cipla announces Q4FY26 and FY26 audited results, dividend, and earnings call details
Cipla · Pharmaceuticals & Biotechnology
Key highlights
- Q4FY26 total income ₹6,541 Cr; EBITDA ₹997 Cr (15.2% margin); PAT ₹555 Cr
- FY26 total income ₹28,163 Cr; EBITDA ₹5,925 Cr (21.0% margin); PAT ₹3,879 Cr
- Final dividend recommended at ₹13 per equity share; earnings call scheduled for May 13, 2026, 1600 hrs IST
Why it's rated major development: the year-on-year change is 55% (20% or more for adverse news)
Figures checked against the filing by a second AI read. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Cipla
- OtherNotableCipla Limited's Scheme of Amalgamation with Inzpera Healthsciences approved by NCLT
- Acquisition / mergerNotableCipla Ltd approves leadership changes, USD 100M investment, and subsidiary merger
- Acquisition / mergerNotableCipla Ltd announces board changes, investment in Cipla (EU) Ltd, and merger approval
Other dividend / buyback / bonus filings this fortnight
- Premco Global Ltd approves Q2 FY 2026-27 results, declares interim dividend, appoints auditor
- Precision Wires India board approves Sept 2026 quarter results and 35% dividend
- Dynamatic Technologies announces Q2 FY27 financial results and interim dividend
- Great Eastern Shipping approves Q2 and H1 results; declares Rs 14.40 interim dividend
- Safari Industries (India) Limited approves Q2 & H1 FY27 results, interim dividend, capex
- IRB Infrastructure Developers announces Q2 & H1 FY27 results and 2nd interim dividend
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.